PLoS One:ICU镇静镇痛药物的年龄相关剂量关系

2017-11-15 佘玉琦 “罂粟花”微信号

重症监护室(ICU)中的镇静和镇痛常基于麻醉方式,而不考虑患者相关因素。ICU麻醉期间镇静剂和镇痛药物的连续输注与推注或短期输注相比,镇静药和镇痛药的药理学特性发生了变化。

背景与目的:重症监护室(ICU)中的镇静和镇痛常基于麻醉方式,而不考虑患者相关因素。ICU麻醉期间镇静剂和镇痛药物的连续输注与推注或短期输注相比,镇静药和镇痛药的药理学特性发生了变化。

方  法:在本前瞻性观察性队列研究中,我们研究了机械通气患者(MV)相关因素与镇静/止痛药剂量之间的关系及其与镇静/镇痛中止的关系。我们纳入机械通气至少24小时的病人,并排除那些难以评估镇静深度的患者。我们收集了72小时内或直到拔管的数据,以先发者优先。使用多变量方差分析,多变量回归和逻辑回归分析数据。

结  果:最终队列(N = 576)主要为男性(64%),平均年龄61.7(15.6)岁,体重63.4(18.2)Kg,急性生理学和慢性健康状况评分Ⅱ为28.2(8),具有30%的住院死亡率。随着年龄的增加,丙泊酚和芬太尼的剂量需求减少,以适应体重(P <0.001)。丙泊酚和芬太尼剂量需求增加的相关的因素是血管加压药的应用(相对平均差(RMD)丙泊酚为1.56(95%置信区间(CI)1.28±1.90);芬太尼为1.48(1.25±1.76),中心静脉置管(CVL,相对平均差(RMD)异丙酚为1.64(1.15±2.33);芬太尼为1.41(1.03±1.91))。男性患者丙泊酚剂量(RMD 1.27(1.06±1.49))需求增加。镇静中止不太可能发生在受限制的患者(OR 0.48(CI 0.30±0.78)或那些接受较高镇静/镇痛剂量的患者(OR异丙酚为0.98(CI 0.97±0.99);芬太尼为0.99(CI 0.98±0.997)),并且与镇静深度无关

结  论:在ICU高龄患者使用较低剂量的镇静/镇痛药物,而中心静脉血管加压素的使用与较高镇静/镇痛药物的使用相关。

原始出处:

Mukhopadhyay A,et al.,Age related inverse dose relation of sedatives and analgesics in the intensive care unit.PLoS One. 2017 Sep 28;12(9):e0185212.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1790074, encodeId=1e1c1e90074f0, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Jul 21 19:20:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933431, encodeId=c9cf1933431d7, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Mon Mar 19 00:20:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355253, encodeId=dd121355253cf, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Nov 17 01:20:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579728, encodeId=5af115e9728a7, content=<a href='/topic/show?id=567c96806cc' target=_blank style='color:#2F92EE;'>#镇痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96806, encryptionId=567c96806cc, topicName=镇痛药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef4d16558274, createdName=ms9476844295372110, createdTime=Fri Nov 17 01:20:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1790074, encodeId=1e1c1e90074f0, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Jul 21 19:20:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933431, encodeId=c9cf1933431d7, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Mon Mar 19 00:20:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355253, encodeId=dd121355253cf, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Nov 17 01:20:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579728, encodeId=5af115e9728a7, content=<a href='/topic/show?id=567c96806cc' target=_blank style='color:#2F92EE;'>#镇痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96806, encryptionId=567c96806cc, topicName=镇痛药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef4d16558274, createdName=ms9476844295372110, createdTime=Fri Nov 17 01:20:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1790074, encodeId=1e1c1e90074f0, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Jul 21 19:20:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933431, encodeId=c9cf1933431d7, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Mon Mar 19 00:20:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355253, encodeId=dd121355253cf, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Nov 17 01:20:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579728, encodeId=5af115e9728a7, content=<a href='/topic/show?id=567c96806cc' target=_blank style='color:#2F92EE;'>#镇痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96806, encryptionId=567c96806cc, topicName=镇痛药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef4d16558274, createdName=ms9476844295372110, createdTime=Fri Nov 17 01:20:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
    2017-11-17 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1790074, encodeId=1e1c1e90074f0, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sat Jul 21 19:20:00 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933431, encodeId=c9cf1933431d7, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Mon Mar 19 00:20:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355253, encodeId=dd121355253cf, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Nov 17 01:20:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579728, encodeId=5af115e9728a7, content=<a href='/topic/show?id=567c96806cc' target=_blank style='color:#2F92EE;'>#镇痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96806, encryptionId=567c96806cc, topicName=镇痛药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef4d16558274, createdName=ms9476844295372110, createdTime=Fri Nov 17 01:20:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]

相关资讯

Med J Australia:研究证明针灸可以镇痛,会逐渐取代镇痛药吗?

世界上最大的使用针灸在急诊部门的随机对照试验发现,该治疗是一种安全有效的一些止痛药物替代疗法。

Yonsei Med J:小儿整形外科术中辅助应用右美托咪定的镇痛的效果优于芬太尼

阿片类药物通常用作局部麻醉剂的硬膜外佐剂,但与潜在的严重副作用(如呼吸抑制)的发生相关。本研究旨在对比右美托咪定与芬太尼作为罗哌卡因硬膜外阻滞在小儿骨科手术中的有效性和安全性。 研究共纳入了60名择期性手术的儿童患者(3 - 12岁),采用患者自控镇痛(PCA)。手术结束前30分钟患者经硬膜外导管接受0.2%罗哌卡因(0.2毫升/公斤)以及右美托咪定(1µg/kg)或芬太尼(1µg/kg)。

EMBO MOL MED:昆明动物所等解密传统中药冰片的外用镇痛作用

近日,中国科学院昆明动物研究所离子通道药物研发中心与上海长征医院合作,首次开展了符合国际标准的冰片临床研究 (参加临床实验总人数达 122 人),解密传统中药冰片的外用镇痛作用。该研究成果发表在 EMBO Molecular Medicine 上,昆明动物所副研究员王树、硕士研究生胡金升和上海长征医院博士张丹为文章共同第一作者。昆明动物所副研究员王树、研究员杨建和上海长征医院教授肖建如为文章共同通

Medicine :臂丛神经阻滞,左布比卡因和罗哌卡因的术后镇痛效果并无差异

在药物的基础上,一般认为左布比卡因较罗哌卡因可持续更长的时间。然而,大多数报告臂丛阻滞时这两种麻醉剂在镇痛效果上并未存在明显的差异。本研究旨在对比左布比卡因和罗哌卡因用于治疗超声引导下臂丛神经阻滞术后的镇痛效果。 研究共纳入62名接受骨科手术的患者,随机接受左布比卡因( L组、n = 31)或罗哌卡因(R组,n = 31  )。记录患者术后镇痛持续时间、运动阻滞偏移时间、术后镇痛药用量及术后

美国妇产科医师学会“2017 产科镇痛和麻醉实践指南”解读

产科麻醉及分娩镇痛是当代产科热点话题,国内外均有大量研究及临床实践,如何规范产科麻醉及分娩镇痛值得每一位产科医护人员思考。2017 年4 月,美国妇产科医师协会颁布了“2017 产科镇痛和麻醉实践指南”,该指南更新了该协会早在2002 年、2004年、2006 年及2007 年颁布的相关指南及专家共识,回顾了分娩期间常用的镇痛和麻醉药物,但是没有提及非药物镇痛,如按摩、水疗、针灸、放松、催眠等辅助

七成疼痛患者未规范化镇痛治疗,阿片类药物用不用?

2017年中国癌症统计年报数据显示,中国癌症患者的数量不断攀升,癌症新发人数增加到459万,占世界的1/4。疼痛是肿瘤患者最常见的伴随性疾病,60%在接受抗肿瘤治疗的患者会出现疼痛,然而70%的疼痛患者未接受规范化的镇痛治疗。“作为目前已发现的镇痛作用最强、止痛疗效最确切的药物,阿片类药物是治疗癌痛的首选,这是世界范围内的共识,得到了美国国立综合癌症网络(NCCN)、欧洲临床肿瘤学会(ESMO)、